# Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

> **NCT03399552** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Malignant Mesothelioma (MPM)

## Interventions

- **DRUG:** Avelumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03399552
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-01-20
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03399552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03399552, "Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03399552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*